Pharsight

Korlym generic

Korlym is an anti-Cushing's syndrome drug owned by Corcept Therap and contains the active ingredient mifepristone. This drug was first authorized for market use on 17 February, 2012 and it has a total of 16 drug patents, none of which have expired so far. Available in tablet; oral dosage forms, the last of Korlym's patents is expected to expire on 22 August 2038.

When will Korlym generic be available?

With a total of 16 patents, Korlym's generic versions could be available post 22 August 2038, after the expiry of the last patent. Until then, Korlym continues to hold exclusive rights to manufacture and distribute this drug for the treatment of Cushing's syndrome.

Korlym uses

Korlym contains mifepristone, which acts as a glucocorticoid receptor antagonist that effectively treats Cushing's syndrome. Various patents held for Korlym pertain to optimizing mifepristone levels for Cushing's patients and differentially diagnosing ACTH-dependent Cushing's syndrome.

Korlym patent expiration

Korlym, owned by Corcept Therap, holds 16 active patents, all focused on the optimization and effectiveness of Mifepristone in treating Cushing's syndrome. The last patent, with a title of 'Use of ACTH in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients', is due to expire on 22 August 2038. Thus, the entry of Korlym generics into the market could be expected post this date. Below are the details of the patent:

Litigations filed on Korlym

Korlym dosage

Want to ask something?